X-Ceptor Therapeutics Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$25.7M
X-Ceptor Therapeutics General Information
Description
Developer of novel small molecule therapeutics that modulate nuclear receptors. The company offers drug discovery platform for the nuclear receptor gene family; and drug candidates to treat cardiovascular and metabolic disorders.
Contact Information
Corporate Office
- 4757 Nexus Centre Drive
- Suite 200
- San Diego, CA 92121
- United States
Corporate Office
- 4757 Nexus Centre Drive
- Suite 200
- San Diego, CA 92121
- United States
X-Ceptor Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Merger/Acquisition | 19-Oct-2004 | $25.7M | Completed | Generating Revenue | ||
| 1. Seed Round | 07-Oct-1999 | Completed | Startup |
X-Ceptor Therapeutics Patents
X-Ceptor Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2005072731-A1 | 3-phenyl-n- ((1, 3, 4) thiadiazol-2-yl) -acrylamide derivatives and related compounds as modulators of estrogen-related receptors for the treatment of e.g. cancer, rheumatoid arthritis or neurological disorders | Inactive | 29-Jan-2004 | ||
| WO-2005056554-A2 | Azepinoindole derivatives as pharmaceutical agents | Inactive | 02-Dec-2003 | ||
| WO-2005056554-A3 | Azepinoindole derivatives as pharmaceutical agents | Inactive | 02-Dec-2003 | ||
| US-20070293464-A1 | Substituted pyrimidine compositions and methods of use | Active | 10-Nov-2003 | ||
| WO-2005047268-A2 | Substituted pyrimidine compositions and methods of use | Inactive | 10-Nov-2003 | A61K31/505 |
X-Ceptor Therapeutics Former Investors (7)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Domain Associates | Venture Capital | Minority | ||
| Farallon Capital Management | Hedge Fund | Minority | ||
| Gimv | PE/Buyout | Minority | ||
| Le Centre CDP Capital | Venture Capital | Minority | ||
| Ligand Pharmaceuticals | Corporation | Minority |
X-Ceptor Therapeutics FAQs
-
When was X-Ceptor Therapeutics founded?
X-Ceptor Therapeutics was founded in 1999.
-
Where is X-Ceptor Therapeutics headquartered?
X-Ceptor Therapeutics is headquartered in San Diego, CA.
-
What industry is X-Ceptor Therapeutics in?
X-Ceptor Therapeutics’s primary industry is Drug Discovery.
-
Is X-Ceptor Therapeutics a private or public company?
X-Ceptor Therapeutics is a Private company.
-
What is the current valuation of X-Ceptor Therapeutics?
The current valuation of X-Ceptor Therapeutics is .
-
What is X-Ceptor Therapeutics’s current revenue?
The current revenue for X-Ceptor Therapeutics is .
-
How much funding has X-Ceptor Therapeutics raised over time?
X-Ceptor Therapeutics has raised $25M.
-
Who are X-Ceptor Therapeutics’s investors?
Domain Associates, Farallon Capital Management, Gimv, Le Centre CDP Capital, and Ligand Pharmaceuticals are 5 of 7 investors who have invested in X-Ceptor Therapeutics.
-
When was X-Ceptor Therapeutics acquired?
X-Ceptor Therapeutics was acquired on 19-Oct-2004.
-
Who acquired X-Ceptor Therapeutics?
X-Ceptor Therapeutics was acquired by Exelixis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
